114676-59-4

114676-59-4 structure

Name: D-Proline, 4-hydroxy-, methyl ester hydrochloride
Chemical Name: D-Proline, 4-hydroxy-, methyl ester, (Hydrochloride) (1:1), (4R)
CAS Number: 114676-59-4
Molecular Formula: C₆H₁₂ClNO₃
Molecular Weight: 181.617
Catalog: Signaling Pathways Antibody-drug Conjugate ADC Linker
Create Date: 2018-08-02 15:50:13
Modify Date: 2025-08-26 06:15:53
D-Proline, 4-hydroxy-, methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). D-Proline, 4-hydroxy-, methyl ester hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2

Name	D-Proline, 4-hydroxy-, methyl ester, (Hydrochloride) (1:1), (4R)
Synonyms	D-Proline, 4-hydroxy-, methyl ester, (4R)-, hydrochloride (1:1) Trans-4-hydroxy-L-proline methyl ester hydrochloride Methyl (4R)-4-hydroxy-L-prolinate hydrochloride (1:1) Methyl (4R)-4-hydroxy-D-prolinate hydrochloride (1:1) CIS-4-HYDROXY-D-PROLINE METHYL ESTER L-Proline, 4-hydroxy-, methyl ester, (4R)-, hydrochloride (1:1) cis-4-hydroxy-D-proline methyl ester hydrochloride methyl cis 4-hydroxyl-D-proline (2R,4R)-4-Hydroxypyrrolidine-2-carboxylic acid methyl ester hydrochloride (2R,4R)-Methyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride

Description	D-Proline, 4-hydroxy-, methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). D-Proline, 4-hydroxy-, methyl ester hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> ADC Linker Signaling Pathways >> PROTAC >> PROTAC Linker
Target	Non-cleavable
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
References	[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

67-56-1

2584-71-6

~99%

114676-59-4

Literature: VICURON PHARMACEUTICALS, INC. Patent: WO2004/7444 A2, 2004 ; Location in patent: Page 135 ;

67-56-1

77449-94-6

~91%

114676-59-4

Literature: Peng, Jianbiao; Clive, Derrick L. J. Journal of Organic Chemistry, 2009 , vol. 74, # 2 p. 513 - 519

2584-71-6

~99%

114676-59-4

Literature: Shionogi Seiyaku Kabushiki Kaisha Patent: US5317016 A1, 1994 ;

75-36-5

2584-71-6

~98%

114676-59-4

Literature: Rosen; Fesik; Chu; Pernet Synthesis, 1988 , # 1 p. 40 - 44

67-56-1

1064036-63-0

114676-59-4

Literature: WO2005/108358 A2, ; Page/Page column 35 ; WO 2005/108358 A2

444313-67-1

114676-59-4

Literature: WO2014/32 A1, ;

51-35-4

114676-59-4

Literature: WO2014/32 A1, ;